

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (currently amended) An assay method for determining whether an agent is capable of modulating the low affinity binding interaction of CCR5 with gp120, the method comprising: incubating the agent with CCR5 and unlabelled gp120 to form a first reaction mixture; adding an anti-gp120 antibody to said first reaction mixture to form a second reaction mixture; and determining whether said agent modulates the interaction of CCR5 with gp120; wherein said gp120 is associated with CD4, and wherein said low affinity binding has a dissociation constant (Kd) of at least 200nM, and wherein said interaction is a low affinity binding.

Claim 2. (cancelled)

Claim 3. (previously presented) The method according to claim 2 1, wherein said ligand anti-gp120 antibody has a detectable label.

Claim 4. (previously presented) The method according to claim 3, wherein said detectable label is a fluorescent atom or a fluorescent group.

Claim 5. (previously presented) The method according to claim 4, wherein said radioactive fluorescent atom is Eu<sup>3+</sup>.

Claim 6. (cancelled)

Claim 7. (cancelled)

Claim 8. (cancelled)

Claim 9. (cancelled)

Claim 10. (cancelled)

Claim 11. (cancelled)

Claim 12. (withdrawn) An agent identified by the method of claim 1, wherein said agent is capable of modulating the interaction of CCR5 with gp120.

Claim 13. (withdrawn) A pharmaceutical composition comprising the agent of claim 12, and one or more pharmaceutically acceptable carriers, diluents, adjuvants, or excipients.

Claim 14. (withdrawn) A method of modulating the *in vivo* interaction of CCR5 with gp120 in a mammal in need thereof, the method comprising administering to said mammal the agent of claim 12.

Claim 15. (withdrawn) The method of claim 14, wherein said agent is administered to treat or prevent human immunodeficiency virus (HIV) infection.

Claim 16. (newly presented) The method according to claim 1, wherein the method further comprises adding to said second reaction mixture a secondary antibody capable of binding to the anti-gp120 antibody.

Claim 17. (newly presented) The method according to claim 16, wherein said secondary antibody has a detectable label.

Claim 18. (newly presented) The method according to claim 17, wherein said detectable label is a fluorescent atom or a fluorescent group.

Claim 19. (newly presented) The method according to claim 18, wherein said fluorescent atom is Eu<sup>3+</sup>.

Claim 20. (newly presented) The method according to claim 16, wherein said secondary antibody is an anti-IgG antibody.

Claim 21. (newly presented) The method according to claim 1, wherein varying concentrations of said agent are incubated with a constant amount of gp120.